CASP9 and hepatocellular carcinoma: To generalise our findings, we treated five commonly used cancer cell lines of colorectal (DLD1, HCT116 and SW480), breast (MDA231) and hepatocellular carcinoma (SNU387) origin with oxaliplatin to activate caspase-9, or death-receptor ligand TRAIL to activate caspase-8,-initiated apoptosis.